Enhancing HIV Care: Overview of New Medications Launched in 2023

Enhancing HIV Care: Overview of New Medications Launched in 2023

The development of new HIV medication is of utmost importance in combating the global HIV epidemic. With the continuous evolution of the virus and the emergence of drug-resistant strains, the need for effective and innovative treatments has become increasingly critical. The introduction of new medications in 2023 brings hope for improved outcomes for HIV patients. These medications, such as Sunlenca (lenacapavir), ViiV Healthcare's cabotegravir, and GSK's integrase strand transfer inhibitors (INSTIs), offer promising mechanisms of action, enhanced efficacy, and greater safety profiles. Additionally, they come with specific dosage and administration guidelines, ensuring optimal usage. The development of these new medications signifies a significant advancement in HIV treatment, providing healthcare professionals and patients with additional options to successfully manage the virus and improve patients' quality of life.

Sunlenca (lenacapavir)

Sunlenca, whose scientific name is lenacapavir, employs a unique method of combatting HIV. This novel treatment disrupts the operation of the critical HIV integrase enzyme, a component that is indispensable to the replication of the virus. By way of this blockade, Sunlenca expertly halts the integration of the viral DNA into the host's DNA, effectively curtailing the virus's ability to propagate within the body. This technique of interference thus introduces Sunlenca as a potential hopeful in HIV treatments, owing to its ability to uniquely target an integral stage in the lifecycle of the virus. Continued investigation and extensive clinical trials are still required to precisely gauge Sunlenca's efficacy, safety standards, as well as its optimum dosage and guidelines for administration. On the whole, however, it is indisputable that Sunlenca's technique of interference exhibits promise towards helping evolve potent HIV treatments for the future.

ViiV Healthcare's cabotegravir

ViiV Healthcare's cabotegravir represents a substantial step forward in HIV therapy. It operates by hindering viral DNA from integrating into the host genome, thereby obstructing the virus's ability to replicate itself. A series of clinical trials have confirmed its potency in both reducing HIV viral load and ensuring sustained viral suppression. Moreover, cabotegravir has manifest a favorable safety record, with minimal side effects reported. Suggested usage and administration protocols recommend injections on a monthly basis - a consideration that constitutes a handy treatment alternative for patients. All in all, the emergence of cabotegravir has brought about significant progress in the field of HIV medications, offering an effective and straightforward treatment route for those grappling with HIV.

new hiv medication 2023

GSK's integrase strand transfer inhibitors (INSTIs)

As part of GSK's portfolio, integrase strand transfer inhibitors (INSTIs) offer a compelling line of defense against the HIV virus, boasting promising outcomes in clinical evaluations. INSTIs function by inhibiting a crucial integrase enzyme, essential for the virus's replication strategy, thereby successfully impeding the incorporation of viral genetic material into the host's DNA. The effect of this inhibition is a pronounced decrease in viral propagation and delay in HIV progression. The range of INSTIs birthed by GSK is impressive, with Dolutegravir leading the pack as the first FDA sanctioned INSTI. These drugs have displayed substantial efficacy in curtailing HIV's viral capacity and revitalizing the immune system. Complementing their effectiveness, they demonstrate an appealing safety character, with minor side impacts and insignificant drug interactions. Concrete dosage and administration instructions have been established for GSK's INSTIs, equipping medical practitioners with comprehensive guidelines to efficiently facilitate and manage these medications. As we look to the future, GSK aims to further bolster the evolution of INSTIs by 2023, with a focus on enhancing the suite of treatment alternatives for individuals grappling with HIV.


  1. Peng, Y., Zong, Y., Wang, D., Chen, J., Chen, Z. S., Peng, F., & Liu, Z. (2023). Current drugs for HIV-1: from challenges to potential in HIV/AIDS. Frontiers in Pharmacology, 14. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637376/)

  2. Sun, L., Nie, P., Luan, L., Herdewijn, P., & Wang, Y. T. (2023). Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update. European Journal of Medicinal Chemistry, 115847. (https://www.sciencedirect.com/science/article/pii/S0223523423008140)

  3. Bernal Santateresa, S. (). A new therapeutical approach to reduce viral persistence, immune activation, and inflammation in people with HIV-1 on antiretroviral therapy. (https://www.tdx.cat/bitstream/handle/10803/689506/tesdoc_a2023_bernal_silvia_new_therapeutical.pdf?sequence=1)

  4. Orkin, C., Arasteh, K., Górgolas Hernández-Mora, M., Pokrovsky, V., Overton, E. T., Girard, P. M., ... & Spreen, W. R. (2020). Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. New England Journal of Medicine, 382(12), 1124-1135. (https://www.nejm.org/doi/full/10.1056/NEJMoa1909512)

  5. Parker, B., Ward, T., Hayward, O., Jacob, I., Arthurs, E., Becker, D., ... & Van de Velde, N. (2021). Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: a modelling study. PLoS One, 16(2), e0245955. (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0245955)

  6. Aberg, J. A., Shepherd, B., Wang, M., Madruga, J. V., Mendo Urbina, F., Katlama, C., ... & Tenorio, A. R. (2023). Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1. Infectious Diseases and Therapy, 1-15. (https://link.springer.com/article/10.1007/s40121-023-00870-6)

  7. Llibre, J. M., Brites, C., Cheng, C. Y., Osiyemi, O., Galera, C., Hocqueloux, L., ... & van Wyk, J. (2023). Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3-or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial. Clinical Infectious Diseases, 76(4), 720-729. (https://academic.oup.com/cid/article/76/4/720/6541246)